Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Fexofenadine New Formulation vs Reference in Healthy Volunteers
NCT06284902Phase 1Completed
- Sponsor
- Sanofi
- Start
- Feb 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fexofenadine in allergic rhinitis (AR) and chronic idiopathic urticaria (CIU) (6 arms), sponsored by Sanofi. Primary endpoints: Area Under the Concentration-time Curve From Time Zero Until the Last Observed Concentration, Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) and 1 more. Started Feb 2024; status: completed.
02
Drugs
fexofenadine
03
Conditions
allergic rhinitis (AR)chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on NCT06284902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06284902.